Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Carcinomas (Including Squamous Cell and Adenocarcinoma)
- 发起方
- Stanford University
- 入组人数
- 2000
- 试验地点
- 1
- 主要终点
- Biomarkers for disease
- 状态
- 招募中
- 最后更新
- 2个月前
概览
简要总结
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
详细描述
This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison
研究者
入排标准
入选标准
- •Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
- •Prior diagnosis of cancer or suspected of having cancer
- •Karnofsky performance status of greater than 70
- •Standard pretreatment evaluation
- •Signed Stanford University Human Subjects Committee consent
排除标准
- 未提供
结局指标
主要结局
Biomarkers for disease
时间窗: Day one